1. Home
  2. OMCL vs NNNN Comparison

OMCL vs NNNN Comparison

Compare OMCL & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Omnicell Inc. ($0.001 par value)

OMCL

Omnicell Inc. ($0.001 par value)

HOLD

Current Price

$34.96

Market Cap

1.5B

Sector

Technology

ML Signal

HOLD

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

HOLD

Current Price

$24.10

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OMCL
NNNN
Founded
1992
2021
Country
United States
Germany
Employees
N/A
N/A
Industry
Computer Manufacturing
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
OMCL
NNNN
Price
$34.96
$24.10
Analyst Decision
Buy
Analyst Count
6
0
Target Price
$53.67
N/A
AVG Volume (30 Days)
517.9K
28.9K
Earning Date
05-05-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.04
N/A
Revenue
$787,309,000.00
N/A
Revenue This Year
$6.77
N/A
Revenue Next Year
$5.22
N/A
P/E Ratio
$857.75
$446.57
Revenue Growth
9.93
N/A
52 Week Low
$22.66
$5.91
52 Week High
$51.84
$55.65

Technical Indicators

Market Signals
Indicator
OMCL
NNNN
Relative Strength Index (RSI) 37.86 52.91
Support Level $33.25 $19.53
Resistance Level $37.51 $30.70
Average True Range (ATR) 1.33 1.96
MACD -0.09 0.40
Stochastic Oscillator 26.83 88.63

Price Performance

Historical Comparison
OMCL
NNNN

About OMCL Omnicell Inc. ($0.001 par value)

Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

Share on Social Networks: